Medipost Expands in US and Canada; Plans US Phase III of Cartistem

Medipost is making significant strides in expanding its operations within the United States and Canada. The company has announced plans to commence a Phase III clinical trial for Cartistem in the US, marking a pivotal step in its strategy to strengthen its foothold in the North American healthcare sector. This move underscores Medipost's commitment to advancing its innovative treatments and therapies to meet the growing demand for regenerative medicine solutions. The expansion and the planned clinical trial are expected to enhance Medipost's capabilities in delivering cutting-edge medical treatments to patients in need, further solidifying its position as a leader in the biotech industry.